Ucb S A (UCBJF) 77.6000 $UCBJF UCB's Vimpat Approved in

New Post Public Reply Private Reply Replies (0) Message Board

Jul 26, 2016 at 11:13 PM

Ucb S A (UCBJF) 77.6000 $UCBJF

UCB's Vimpat Approved in Japan for Partial Onset Seizures
Zacks Equity Research - Zacks Investment Research - Wed Jul 06, 9:47AM CDT
UCB (UCBJF) and Daiichi Sankyo announced that Vimpat was approved in Japan as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy.
JNJ: 125.15 (+0.26), ABBV: 64.45 (+0.13), NVS: 83.02 (-0.44)

Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 43.60 (+0.19), JNJ: 125.15 (+0.26), RDY: 44.11 (-7.99)

UCB (UCBJF) Posts Q1 Results, Reiterates 2016 Guidance
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 10:23AM CDT
UCB (UCBJF) reported interim results for the first three months of 2016.
EBS: 33.44 (+0.20), GILD: 81.05 (-7.50), SHPG: 193.60 (+1.31)

UCB: CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS
Globe Newswire - Fri Mar 25, 3:01AM CDT
*** Unofficial English translation - For convenience purposes only ***

Dr. Reddy's Q3 Earnings Up Y/Y, Warning Letter in Focus
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 10:06AM CST
Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2016 earnings per American Depositary Share of 51 cents, up 1% from the year-ago quarter.
ATRA: 22.83 (unch), BXLT: 46.02 (-0.18), RDY: 44.11 (-7.99)

ZS Pharma Soars on $2.7B Buyout Offer from AstraZeneca
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 11:50AM CST
AstraZeneca (AZN) will acquire biotech company ZS Pharma (ZSPH) for about $2.7 billion, boosting its cardiovascular & metabolic disease portfolio and pipeline.
ZSPH: 89.98 (+0.06), AZN: 30.91 (-0.24)

Aerie (AERI) Posts Narrower-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 9:40AM CST
Aerie (AERI) reported third-quarter 2015 loss of 69 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 81 cents.
ADHD: 4.25 (+0.09), AERI: 17.38 (+0.09), SPPI: 6.51 (+0.04)

Dr. Reddy's (RDY) Q2 Earnings Rise Y/Y, Biosimilars in Focus
Zacks Equity Research - Zacks Investment Research - Fri Oct 30, 10:16AM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 64 cents, up 25.5% from the year-ago quarter.
ANAC: 99.06 (-0.14), RDY: 44.11 (-7.99), CORT: 5.82 (-0.13)

Valeant (VRX) Loses Over 5% Despite Business Model Review
Zacks Equity Research - Zacks Investment Research - Tue Oct 27, 1:22PM CDT
Investigations into Valeant's (VRX) drug pricing policies and accusations related to its business model continue. The company has an uphill battle ahead.
LCI: 30.45 (-0.21), VRX: 23.05 (+0.20), ANAC: 99.06 (-0.14)

Valeant (VRX) in Focus on Intensifying Government Probe
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:20PM CDT
Valeant (VRX) has hit a rough patch ever since concerns arose about the irrational increase in drug prices by U.S. pharma/biotech companies.
LCI: 30.45 (-0.21), VRX: 23.05 (+0.20), ANAC: 99.06 (-0.14)

Prothena to Start Phase IIb Study on AL Amyloidosis Drug
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:10PM CDT
Prothena (PRTA) announced that it will commence a phase IIb study on NEOD001 for patients suffering from AL amyloidosis and persistent cardiac dysfunction.
LCI: 30.45 (-0.21), ANAC: 99.06 (-0.14), PRTA: 51.61 (-0.61)

Shire's Cinryze Gets Fast Track Status for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:45PM CDT
Shire announced that its HAE drug Cinryze has been granted Fast Track designation for antibody mediated rejection (AMR) in renal transplant recipients by the FDA.
LCI: 30.45 (-0.21), SHPG: 193.60 (+1.31), AZN: 30.91 (-0.24)

UCB Reveals Positive Data on Vimpat Monotherapy Study
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:45PM CDT
UCB (UCBJF) announced encouraging top-line results from a phase III non-inferiority study on Vimpat monotherapy for newly diagnosed partial-onset seizures.
ADHD: 4.25 (+0.09), APRI: 0.35 (-0.01), ANAC: 99.06 (-0.14)

Catalyst Starts Congenital Myasthenic Syndromes Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 1:35PM CDT
Catalyst Pharmaceuticals (CPRX) initiated a pediatric study on Firdapse for congenital myasthenic syndromes in patients aged 2 years to 17 years.
BMRN: 92.02 (-0.77), CPRX: 0.75 (unch), APRI: 0.35 (-0.01)

Lannett (LCI) to Buy UCB's Specialty Generics Subsidiary
Zacks Equity Research - Zacks Investment Research - Thu Sep 03, 3:10PM CDT
Lannett Company (LCI) inked a deal with UCB to buy its U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals Inc.
LCI: 30.45 (-0.21), JNJ: 125.15 (+0.26), CORT: 5.82 (-0.13)

Amgen, Novartis Team Up; Bone Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Wed Sep 02, 3:50PM CDT
Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
AMGN: 167.67 (+1.11), LLY: 82.09 (+0.11), NVS: 83.02 (-0.44)

Dr. Reddy's Q1 Earnings & Revenues Rise Y/Y, Offers View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 31, 2:07PM CDT
Dr. Reddy's Laboratories (RDY) reported first-quarter fiscal 2016 earnings per American Depositary Share (ADS) of 58 cents, up 13.7% from the year-ago quarter.
AGN: 248.95 (+1.10), PGNX: 5.98 (+0.06), RDY: 44.11 (-7.99)

UCB to Expand Cimzia Label Based on Positive Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 15, 1:50PM CDT
UCB S.A. (UCBJF) announced positive results from a phase III study on Cimzia for rheumatoid arthritis in DMARD-naive patients at high risk of disease progression.
VRX: 23.05 (+0.20), BIOD: 0.39 (+0.05)

Immunomedics' Drug Gets Fast Track Status for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 3:39PM CDT
Immunomedics, Inc. (IMMU) announced that the FDA has granted fast track designation to its lead antibody-drug conjugate program sacituzumab govitecan for the treatment of patients suffering from metastatic non-small cell lung cancer.
VRX: 23.05 (+0.20), IMMU: 2.64 (+0.05), PFE: 36.83 (+0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WellLink Advisory Board Eyes Future of Healthcare Innovation

Strategic Collaboration for Healthcare Evolution Ready to shake things up in healthcare, WellLink is setting the stage with its brand new Advisory Board. This move isn’t just about having fancy titles sitting around a conference table — it's about grabbing onto the future with both hands and figuring out just what the heck the healthcare industry needs next....

Mutare Sharpens Security for Webex Calls with Precision

Control Dialed In: Tailored Call Screening Kicking things up a notch, Mutare is redefining call security by fine-tuning their Voice Security for Webex Calling. Imagine this—custom rules now let organizations shape a security policy down to the very last detail, ensuring unwanted calls don’t slip through the cracks. Wave goodbye to the broad-strokes approach. Precision...

TWP & Commbi Unveil Exclusive Pony Clog Collaboration

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Alcott HR's Sales Strategy Gets a Boost with New Hire

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

CSS Revamps Identity, Emphasizing Senior Living Tech

CSS Takes a Bold Step with a Fresh Brand Identity Every now and then, you see a company shake off the old coat and put on a polished new one. That's what CSS is doing with its updated brand, staking its claim as a heavyweight tech player in the senior living sector. No small feat, given the challenges stacked against these aging communities—tasked with keeping...

Cabot Wilds: Nova Scotia's Next Luxury Golf Haven

Breaking New Ground in Golf and Luxury Cabot and the Bragg family are cooking up something extraordinary in Cumberland County, Nova Scotia. The new luxury lifestyle and golf destination, Cabot Wilds, promises to be more than just a retreat—it's a bold statement on how to marry nature, luxury, and community. Set to open in late 2027, this expansive 2,500-acre resort will...

Rosewood HK Tops Best Hotel List Again; Asia Shines

Holding the Crown: Rosewood Hong Kong's Triumph When a single hotel keeps nabbing the top spot in the world's most prestigious rankings, it's worth taking a closer look. That's exactly what's happening with Rosewood Hong Kong, crowned the world's best once more in 2026—its second consecutive year at the pinnacle according to The 50 Best Hotels. Defining Luxury on a...

Feeding Families Foundation Gains $121,500 for NYC Push

Holy smokes, here comes some good news in the nonprofit corners! Feeding Families Foundation just got a hefty $121,500 boost from the Association of Contracting Plumbers of the City of New York Inc. This ain't just some pocket change; it's a full-fledged lifeline that helps them keep on delivering meals to parents who are practically living at their kid’s hospital...